跳至主要内容
临床试验/ISRCTN86879094
ISRCTN86879094已完成未知

Exercise training in Diastolic Heart Failure: A prospective, randomized, controlled study to determine the effects of exercise training in patients with heart failure and preserved ejection fraction

Georg-August University of Gottingen (Georg-August-Unversitat Gottingen) (Germany)0 个研究点目标入组 320 人开始时间: 2011年10月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
320

研究概览

简要总结

2017 Protocol article in https://pubmed.ncbi.nlm.nih.gov/28516519/ protocol (added 12/08/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Stable symptomatic heart failure with preserved ejection fraction (diagnosis according to criteria of the European Society of Cardiology: Paulus et al., 2007):
  • 1.1. New York Heart Association (NYHA) II-III, peak VO2 < 25 ml/kg/min
  • 1.2. Left ventricular ejection fraction (LVEF) = 50%
  • 1.3. Ratio of early transmitral flow velocity (E) to early diastolic mitral annular velocity (E') (E/e)' > 15 or (E/e') > 8 < 15
  • 1.4. N-terminal pro-B-type natriuretic peptide (NTproBNP) > 220 ng/L
  • 1.5. Atrial fibrillation
  • 2. Age =18 years
  • 3. Symptom severity and heart failure medication were stable during the last 4 weeks
  • 4. Written informed consent of the patient

排除标准

  • 1. Non-cardiac causes for heart failure like symptoms:
  • 1.1. Chronic obstructive pulmonary disease (COPD) - Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages = II (moderate, severe, very severe)
  • 1.2. Anaemia (<11mg/dl)
  • 1.3. Significant renal dysfunction estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73m^2 body surface area (BSA)
  • 1.4. Significant peripheral artery disease (Fontaine = IIb)
  • 1.5. Musculoskeletal disease that contribute to reduced exercise performance
  • 1.6. Specific cardiomyopathy (e.g. amyloidosis etc.)
  • 1.7. Haemodynamically significant valvular disorders
  • 2. Significant coronary artery disease (CAD) [current angina pectoris, Canadian Cardiovascular Society (CCS) = II or positive stresstest, myocardial infarction or coronary artery bypass graft within the last 3 months)
  • 3. Any inability or contraindication to participate in ergospirometric testing or in an exercise program (e.g. physiological, mental) or supply essential information (e.g. questionnaire, diary)
  • 4. Ineffective control of resting blood pressure (BP >=140/90mmHg or BP >= 160/100mmHg with >= 3 antihypertensive drugs) or of resting heart rate (HR >= 100bpm)
  • 5. Expected low compliance (e.g. by travel distance to trial site; planned absences longer than 4 weeks during follow up) or ongoing drug abuse
  • 6. Concomitant participation in other interventional clinical trials

研究者

发起方
Georg-August University of Gottingen (Georg-August-Unversitat Gottingen) (Germany)

相似试验